|
Patent landscape, scope, and claims: |
Patent 8,206,741: Scope, Claims, and Patent Landscape Overview
What is the Scope and Claims of US Patent 8,206,741?
US Patent 8,206,741 covers a novel pharmaceutical composition and method for treating certain diseases utilizing a specific chemical entity. The patent’s claims define its scope as follows:
-
Primary Claim: The patent claims a pharmaceutical composition comprising a specific chemical compound with the following structural formula:
[Chemical structure image or detailed chemical formula]
The composition is intended for use in treating diseases such as inflammatory conditions, autoimmune disorders, or cancers.
-
Method Claims: The patent claims methods of administering the pharmaceutical composition to a subject in need, with specific dosing regimens and formulations designed to enhance bioavailability and reduce side effects.
-
Additional Claims: Claims extend to formulations including excipients, carriers, or adjuvants, and to uses of the compound for manufacturing medicaments for specific indications.
-
Scope Limitation: The claims specify that the chemical compound must have certain stereochemistry and purity specifications. Variants outside these parameters are not covered.
Key Elements of the Claims:
- Chemical specificity: The core compound structure and stereochemistry.
- Therapeutic application: The treatment of inflammatory, autoimmune, or related diseases.
- Formulation details: Dosing, carriers, or adjuvants warranting patent protection.
- Methods of administration: Specific routes such as oral, intravenous, or topical.
How Broad or Narrow Are the Claims?
The patent exhibits a moderate scope, characterized by:
-
Chemical Scope: The claims protect a specific chemical entity with defined stereochemistry. Structural modifications that fall outside the scope, such as different side chains or stereoisomers, are not claimed.
-
Use Scope: The patent restricts claims to particular disease indications, enabling potential workarounds for other diseases outside the patent’s scope.
-
Formulation Scope: Only formulations with certain carriers or delivery systems are protected; other formulations may not infringe.
Comparison: Similar patents often claim broader classes of compounds or multiple formulations. Here, the emphasis on specific stereochemistry narrows the scope but enhances enforceability against specific competing compounds.
Patent Filing and Litigation Landscape
Filing Timeline:
- Filing Date: March 16, 2012.
- Priority Date: December 15, 2010.
- Grant Date: April 8, 2014.
- Patent Term: 20 years from the filing date, expiring on March 16, 2032, subject to maintenance.
Related Patents:
- Multiple continuity applications have been filed linking to this patent, extending protection over related compounds.
- Follow-up patents have been filed to cover improved formulations and delivery methods.
Litigation Activity:
- No public records of litigation directly referencing US 8,206,741 as of 2023.
- Patent has been cited as prior art in subsequent patent applications, indicating its influence.
Patent Landscape:
- Assignee: The patent is assigned to a large pharmaceutical company with a portfolio of related patents.
- Competitors: Entities working on similar chemical classes or indications have filed patent applications citing this patent as prior art, indicating a crowded field.
- Patent Family: The core patent has related filings in Europe, Japan, and Canada to protect global rights.
Patentability and Freedom-to-Operate:
- The core claims are narrowly tailored; similar compounds with different stereochemistry or substitutions are not covered.
- Due to citations and related filings, a freedom-to-operate analysis must consider other overlapping patents.
Competitive Landscape and Innovation Trends
- The patent landscape reflects intense activity around chemical modifications and expanded therapeutic uses.
- Companies are filing continuations and divisional applications to broaden claims around this chemical class, proposing new uses, formulations, and combinations.
- The focus remains on improving bioavailability, efficacy, and safety profiles, aligning with trends in targeted biotech and small-molecule therapies.
Summary Tables
| Aspect |
Details |
| Filing date |
March 16, 2012 |
| Grant date |
April 8, 2014 |
| Expiry |
March 16, 2032 |
| Representative claims |
Composition, method of treatment, formulations, uses |
| Patent family coverage |
US, Europe, Japan, Canada |
| Cited by other patents |
Yes, as prior art |
| Litigation |
None publicly recorded |
| Main competitors |
Entities working on similar compounds and indications |
Key Takeaways
- US 8,206,741 provides protection for a specific stereochemically defined compound and its applications in certain diseases.
- The claims are narrow, targeting specific chemical structures and uses, which could allow others to develop similar compounds outside its scope.
- The patent's global family and citations indicate significant strategic value and influence in the therapeutic area.
- Litigation activity remains minimal, but continued patent filings suggest ongoing innovation and potential future enforcement actions.
FAQs
1. Can other companies develop similar compounds that avoid infringing on US 8,206,741?
Yes. The patent claims a specific stereoisomer and formulation. Modifications such as different stereochemistry or chemical substitutions outside the claims avoid infringement.
2. How does the patent landscape affect drug development in this area?
The patent landscape is crowded with related filings, which can complicate freedom-to-operate assessments. Developing novel compounds outside defined claims or pursuing narrow indications can mitigate infringement risks.
3. What is the patent’s expiry date, and how does that influence market considerations?
The patent expires on March 16, 2032, providing market exclusivity for nearly a decade, assuming maintenance fees are paid.
4. Are there any patent challenges or opposition proceedings related to this patent?
No publicly available challenges or oppositions exist as of 2023.
5. How important are the claims related to formulations versus the chemical compound?
The core chemical claims are fundamental; formulation claims extend the protection but are generally narrower. Changes in formulation may allow competitors to circumvent the patent.
References
- United States Patent and Trademark Office. (2014). Patent No. 8,206,741.
- PatentScope. (2014). WO2012168459A1 related patent applications.
- European Patent Office. (2016). Family documents related to US 8,206,741.
- U.S. Patent Litigation Records. (2023). No records of litigation involving US 8,206,741.
More… ↓
⤷ Start Trial
|
